Clonidine in the management of mild hypertension in twenty-two patients
CLONIDINE* (ST-155) is an imidazoline derivative [2-(2,6-dichloro-phenylamino)-2-imidazoline hydrochloride] which has been reported to have depressor action in animals1–4 and in man.5–7 Its hypotensive effect is mediated by central suppression of the sympathetic nervous system.1–4 Davidov, Kakaviatos, and Finnerty5 reported that oral administration of clonidine produced a slight increase in cardiac output and a decrease in peripheral resistance in six hypertensive patients; whereas, Onesti and associates7 found that clonidine given orally resulted in a consistent reduction in cardiac output with no change in peripheral resistance in seven hypertensive patients. Kroetz and colleagues8 reported that intravenous administration of clonidine produced a decrease in cardiac output with no change in peripheral resistance in six hypertensive patients.
This report presents an analysis of a program of therapy consisting of the oral administration of clonidine to 22 mildly hypertensive patients for periods of from 2 to 26 months.
Selection of patients and design of study
Patients with mild hypertension were selected for this study on the basis of their willingness to cooperate. Many of the patients had participated in previous drug studies and had proved to be reliable with regard to the taking of medication and the keeping of appointments. Patients with severe hypertension or those with impending complications were not included in this study.
There were 9 men and 13 women—5 Caucasian and 17 Negro. The ages of the patients ranged from 38 years to more than 70 years (Table 1).
All the patients underwent extensive diagnostic evaluation and it was concluded that . . .